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Abstract
Most people in the world (~90%) are infected by the Epstein–Barr virus (EBV), which establishes itself permanently in B cells. Infection
by EBV is related to a number of diseases including infectious mononucleosis, multiple sclerosis, and different types of cancer. So far,
only seven complete EBV strains have been described, all of them coming from donors presenting EBV-related diseases. To perform a
detailed comparative genomic analysis of EBV including, for the first time, EBV strains derived from healthy individuals, we recon-
structed EBV sequences infecting lymphoblastoid cell lines (LCLs) from the 1000 Genomes Project. As strain B95-8 was used to
transform B cells to obtain LCLs, it is always present, but a specific deletion in its genome sets it apart from natural EBV strains. After
studying hundreds of individuals, we determined the presence of natural EBV in at least 10 of them and obtained a set of variants
specific to wild-type EBV. By mapping the natural EBV reads into the EBV reference genome (NC007605), we constructed nearly
completewild-typeviralgenomesfromthree individuals.Addingthemtothefivedisease-derivedEBVgenomicsequencesavailable in
the literature, we performed an in-depth comparative genomic analysis. We found that latency genes harbor more nucleotide
diversity than lytic genes and that six out of nine latency-related genes, as well as other genes involved in viral attachment and
entry into host cells, packaging, and the capsid, present the molecular signature of accelerated protein evolution rates, suggesting
rapid host–parasite coevolution.
Key words: recombination, selection, human herpesvirus 4, EBV, Illumina reads, whole-genome analysis.
Introduction
Human herpesvirus type 4, or Epstein–Barr virus (EBV), is a
dsDNA virus with a genome size of around 170 kb. The EBV
infects more than 90% of adults worldwide (Chang et al.
2009). Usually, the primary infection occurs early in life and
is asymptomatic in children, while in young adults can produce
infectious mononucleosis (IM). EBV preferentially infects B cells
but can also attach to and enter into epithelial cells (Borza and
Hutt-Fletcher 2002). Upon infection, EBV establishes life-long
latency in the form of episomes residing in the host cell’s nu-
cleus. Only a small subset of the ~90 coding regions of the
virus are expressed in latency: six nuclear proteins (EBNA-1, -2,
-3A, -3B, -3C, and -LP) and three membrane proteins (LMP-1,
-2A, and -2B) (Young and Rickinson 2004).
Infection by EBV has been related to a number of complex
diseases including multiple sclerosis (MS) and different types of
cancer such as Burkitt’s lymphoma (BL), Hodgkins’ lymphoma
(HL), or nasopharyngeal carcinoma (NPC) and gastric
GBE
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carcinoma (GC). The prevalence of these diseases varies with
geography. For instance, NPC is much more prevalent in Asia,
whereas BL is found most commonly in equatorial Africa
(Chang et al. 2009); another notorious example is given by
MS, which has greater prevalence in higher latitudes in
Caucasian populations, while it is extremely rare in the
Tropics (Ascherio and Munger 2010). A number of studies
have tried to relate genetic variability of EBV strains to the
prevalence of these diseases or to broadly defined geograph-
ical regions. Such efforts have focused on sequencing genes
that play important roles in essential viral processes, such as
BZLF1 (Gutie´rrez et al. 2002; Martini et al. 2007), EBNA-1
(Habeshaw et al. 1999; Brennan et al. 2010; Lorenzetti
et al. 2010; Wang, Liu, Xing et al. 2010), EBNA-2 (Aitken
et al. 1994), EBNA-3A, -3B, and -3C (Go¨rzer et al. 2006),
LMP-1 (Edwards et al. 1999, 2004), and LMP-2a (Wang, Liu,
Jia et al. 2010). However, the few studies that have classified
EBV strains using combinations of variants from more than
one gene suggest that recombination does take place and
that many variant combinations are possible, thus increasing
the difficulty of typing EBV strains (Gutie´rrez et al. 2000;
Chang et al. 2009; Sawada et al. 2011).
The study of the worldwide distribution of the genetic var-
iability of EBV and its potential contributions to the risk of
disease would benefit from the analysis of whole EBV ge-
nomes. So far, only seven EBV strains have been completely
sequenced: the B95-8/Raji strain from an American patient of
IM; AG876 and MUTU from African individuals with BL; and
the GD1, GD2, HKNPC1, and AKATA strains from Asian indi-
viduals with NPC or BL (Baer et al. 1984; Zeng et al. 2005;
Dolan et al. 2006; Liu et al. 2011; Kwok et al. 2012; Lin et al.
2013) (supplementary table S1.1, Supplementary Material
online). All these strains were derived from diseased
individuals.
We set out to perform a comprehensive comparative ge-
nomic study of EBV. Rather than limiting ourselves to the pub-
lished strains, we add new information by reconstructing EBV
sequences extracted from lymphoblastoid cell lines (LCLs) be-
longing to healthy individuals who were fully sequenced
within the 1000 Genomes Project (1kG Project) (Durbin
et al. 2010). To obtain a steady source of DNA for genetic
studies, cell cultures of LCLs were established by transforming
each donor’s B cells with the B95-8 EBV strain. Thus, that
strain is always present in all individual LCL cultures and may
have eliminated all traces of endogenous EBV strains.
However, B95-8 presents a specific 12-kb deletion in its
genome that was spontaneously produced in the laboratory
(Skare et al. 1982), allowing us to distinguish between natural
and artificial EBV strains. We were able to determine the pres-
ence of natural EBV in at least ten individuals. A complete set
of natural nucleotide variants was obtained from three of
them. Adding these three new sequences to the already
known complete EBV genomes, we were able to carry out
analyses exploring genome diversity, phylogenetic
relationships, and possible recombination events among EBV
strains. Finally, we conducted an analysis of rates of protein
evolution of viral genes.
Materials and Methods
Origin of Individual LCLs
The samples sequenced within the 1000 Genomes Project
came from LCLs established from blood at the nonprofit
Coriell Institute for Medical Research. We used sequence
reads from the 1kG release 20101123, with 1,103 available
individual alignments to the reference human assembly. The
analysis shown here is based on the 929 individuals who were
sequenced using Illumina technology with paired-end se-
quenced DNA libraries. We retrieved reads that do not map
to the human genome and are labeled as “unmapped” for
each individual in the 1kG Project database.
Mapping
Unmapped reads were mapped against the EBV reference
genome (NC_007605), a composite of the B95-8 strain and
12 kb from the Raji strain to correct the nonnatural B95-8-
specific deletion from position 139,724 to 151,554. Previous
to mapping, we masked the reference EBV genome using
RepeatMasker (Smit et al. 1996–2010) to remove low-com-
plexity regions. We also masked a large region of repeats be-
tween positions 12,001 and 35,355. Mapping was performed
using BWA (Li and Durbin 2010) with default parameters.
After that, we removed duplicated read-pairs using
SAMtools (Li et al. 2009). We kept only paired-reads with
both reads mapping uniquely to the EBV genome. We deter-
mined INDELs and realigned reads falling around them using
GATK (DePristo et al. 2011), and finally, we recalibrated base
quality scores of the aligned reads by considering empirical
Phred scores at the level of cycle effect (position in read)
and dinucleotide mismatch distribution (the effect of the pre-
ceding nucleotide).
Variant Calling
We called variants from pileup files produced by SAMtools
based on cut-offs at the level of coverage (10), phred-
score (20), and a minimum number of reads supporting a
variant (2). We filtered out those variants with extreme
strand bias and an allele balance lower than 5%. INDELs
were called with the same cut-offs using VarScan (Koboldt
et al. 2009). Variants calling in the B95-8-specific deletion
were refined using VarScan relaxing coverage cut-offs. Only
variants present in the nonrepetitive region of EBV were used
for subsequent analysis. In addition to the already masked
region identified by RepeatMasker, we also ignored variants
in specific repeats in the EBV genome reference genome
(NC_007605) according to GenBank annotation. The total
EBV Natural Strains from 1000G Project Individuals GBE
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length of the evaluated EBV genome was 135,486 bp out of
~172 kb (~79% of the total).
PCR Amplification, Cloning and Sanger Sequencing
hDNA templates NA19114, NA19315, and NA19384 were
purchased from Coriell Cell Repositories. Oligonucleotide
primer pairs were EBNA-2Fw: 50-ggatgcctggacacaagag-30
and EBNA-2Rev: 50-tgtgctggtgctgctgg-30, BBLF4Fw: 50-agac-
gatgcagggaatgc-30 and BBLF4Rev: 50-agaggcgctctcgtccac-30,
LF2Fw: 50-agccactgaggaagatctgg-30 and LF2Rev: 50-gaagct-
taccccggaggag-30. The High Fidelity Taq DNA Polymerase
KAPA HiFi (Cultek) was used and PCR amplification conditions
comprised an initial denaturation of 3 min at 95 C, followed
by 35 cycles of 98 C for 20 s, 60 C for 15 s, and at 72 C for
15 s with a final extension at 72 C for 5 min. The PCR prod-
ucts were purified according to the QIAquick Gel Extraction kit
instructions (Qiagen). The DNA fragments of interest were
ligated into the pGEM-T easy vector at 4 C overnight accord-
ing to manufacturer’s instructions (pGEM-T Easy cloning kit,
Promega) (in the case of the amplified product using EBNA-2
primers with the NA19114 template, DNA was digested with
BspHI and the undigested fragment was selected for ligation).
The products were transformed into competent DH5a bacte-
ria. Positive recombinants were selected on LB-ampicillin/IPTG/
X-gal plates and plasmid DNA was purified from overnight
culture using QIAGEN Miniprep kit (Qiagen). The presence
of the fragment of interest was verified by RsaI and EcoRI
restriction digestion. Positive DNA plasmids were sequenced
by Macrogen, Inc.
Analysis and Representation
Individual LCLs EBV genome sequences were obtained by in-
corporating called SNVs into the reference EBV sequence.
Most statistical analyses were performed using R packages.
Manipulation of sequence intervals was carried out with
IRanges (Pages et al.). Principal component analysis (PCA)
was performed using the R package prcomp (R
Development Core Team 2012), on SNVs without scaling var-
iables to avoid overcontribution of rare variants (McVean
2009). Significance level of all principal components (PCs)
was computed calculating the Tracy-Widom statistic to each
PC eigenvalue (Johnstone 2001; Patterson et al. 2006). We
estimated putative recombination breakpoints among EBV
strains using Recco (Maydt and Lengauer 2006). Each recom-
bination block was compared pairwise measuring genetic
identity with the seqinr R package (Charif and Lobry 2007).
Plots were performed using the ggplot2 package (Wickham
2009) and Circos software (Connors et al. 2009).
Phylogenetic trees were constructed using Phyml (Guindon
et al. 2010) with the command line: phyml –i OUR_SEQs.phy
-d nt -b 1000 -m K80 -v e -c 1 -a e -o n -s NNI with 1,000
bootstrap. We performed dN/dS analysis using model 0 in
codeml from PAML (Yang 2007), which gives one o ratio
for all lineages and considering the global tree resulting
from the alignment of the whole EBV sequences. The NSites
parameter, which sets variation between sites, was used to
test one o ratio (NSites¼ 0) or different os values between
codons (NSites¼ 7, which allows o between 0 and 1; and
NSites¼ 8, which allows o to be greater than 1). Different
models were compared as usual in these cases. First NSites
0 versus NSites 0 fixing o at 0.22 or 1 were compared with a
log likelihood test with one degree of freedom. NSites 7 versus
8 was compared with a log likelihood test with two degrees of
freedom. Robustness ofo estimates were assessed by produc-
ing all possible topologies with eight final branches using
PAUP* 4.0b10 (Swofford 2003) and reestimating o in each
of them.
Finally, alignment visualization tools included IGV viewer
(Thorvaldsdo´ttir et al. 2013) and Geneious Pro 5.6.3.
Results
Identification of Natural EBV Strains
To evaluate the presence of natural EBV strains, we measured
coverage in the region corresponding to the 12-kb B95-8 de-
letion and compared it with the average coverage in the rest
of the masked viral genome (127,219 bp). Overall EBV cover-
age varied greatly among the analyzed individuals, ranging
from 0 to 1,622.45. The mean and median coverage
were 111.9 and 65.9, respectively. We required that
each strain presented a minimum median coverage of 20
to be included in the analysis, which left a set of 784 individ-
uals. The average median coverage for them was 123.3,
with 90% of the individuals presenting a coverage >20 in
at least 99.9% of the genome (supplementary material S2,
Supplementary Material online).
Uniquely mapping reads (mapped only once) in the B95-8
deletion indicate the presence of wild-type EBV. However, the
B95-8 deletion contains two repeat regions (IR4 and DRright)
that could generate false positives. Thus, coverage was calcu-
lated only for the single-copy region immediately after these
repeats (7 kb between positions 144,445 and 151,554). The
results suggested the presence of natural strains in some LCLs
(fig. 1). The median coverage in the deletion region in the 784
individuals was 0.002. A total of 61 LCLs showed no
uniquely mapping reads at the deletion coupled with an over-
all median EBV coverage of at least 20, suggesting that they
are exclusively infected by the transforming strain. Traces of
wild-type EBV were detected in 711 LCLs, but in these cases
mean coverage in the deletion region was <1, not high
enough for variant calling. Finally, 12 individuals (1.53%) pre-
sented a mean coverage greater than 1 in the B95-8 dele-
tion, with five of them reaching a coverage >10. We set a
threshold for mean deletion coverage plus one standard de-
viation (2.1) to bring any individual to further analysis. This
left a set of ten individuals with detectable natural EBV levels.
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848 Genome Biol. Evol. 6(4):846–860. doi:10.1093/gbe/evu054 Advance Access publication March 28, 2014
 at Centro de Inform
aciÃ³n y DocumentaciÃ³n CientÃ-fica on M
arch 20, 2015
http://gbe.oxfordjournals.org/
D
ow
nloaded from
 
All ten naturally infected LCLs are shown in table 1 ordered
according to the proportion of natural EBV coverage, as esti-
mated by the ratio between average coverage present in the
B95-8-specific deletion and overall EBV average coverage.
Five out of the ten cell lines contained a proportion of the
natural virus that is around or below the 5% allele balance
cut-off that was used to call variants (see Materials and
Methods). However, in the five LCLs with higher natural
EBV load, the proportion of natural EBV ranged from ~16%
to ~80%. These were four Kenyans (LWK, individuals
NA19384, NA19380, NA19315, and NA19474) and one
Yoruba (YRI, individual NA19114). For these individuals, we
estimated the expected proportion of their EBV genomes cov-
ered by natural EBV, assuming that coverage follows a Poisson
distribution. The probability of having all EBV genome covered
by at least two reads of the natural strain is given by
P X  2ð Þ ¼ 1  e  e 
where l is the average coverage per nucleotide at the B95-8
deletion and k the total length of the viral genome in base
pair. This simple calculation suggests that, with a 95–100%
probability, all endogenous viral genome is covered by at least
two natural EBV reads in individuals NA19114, NA19315, and
NA19384, with the figure dropping to 84.5% and 11.5%,
respectively, for individuals NA19380 and NA19474. In con-
clusion, natural EBV can be detected in at least three cell lines
with reliability high enough for variant calling. Of course, this is
a probabilistic approach, and even if probabilities are quite
high it is not possible to have absolute guarantee that there
are no regions with no coverage from the natural genome.
Measuring Nucleotide Diversity
All evidence indicates that variability levels in the transforming
strain B95-8 are extremely low. Only 279 positions were pu-
tatively polymorphic among the 61 LCLs, which were infected
solely with the transforming strain. Out of these 279 variants,
only 7 showed an allele balance for the alternative allele
greater than 0.8, suggesting that they are sequencing arti-
facts. Moreover, all 279 variants, but one, were present in a
single individual. Five individuals share this common variant,
which is found at position 70,269 in a region with no anno-
tated functional elements. In summary, each of these 61 in-
dividuals is infected by a B95-8 strain which is nearly identical
to the reference. Interestingly, this allows for an estimation of
0
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FIG. 1.—Boxplot of the coverage for all LCLs in the whole EBV genome (right) and in the B95-8-specific deletion (left). The inner panel displays a zoom in
the coverage scale that shows that coverage at B95-8 is nonzero, suggesting the presence of natural EBV in some LCLs.
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the amount of artifactual variants expected in individuals that
carry the natural strain: given that each one of these 61 LCLs
presents five low-quality variants on average, a similar number
of false positives should be expected in individuals that also
carry variants from the endogenous, wild-type EBV.
In sharp contrast to the lines infected solely with the trans-
forming strain, diversity levels were much higher in all the LCLs
showing high coverage at the B95-8 deletion. Allele balances
were also higher, indicating that these variants had been con-
fidently called (table 1 and fig. 2). In total, we observed 1,534
single nucleotide variants (SNVs) in the 10 LCLs with the high-
est coverage at B95-8 deletion. As expected if the
endogenous virus contributed them, these are high-quality
variants and their allele balance is highly correlated with the
proportion of natural EBV reads over total EBV coverage
(R2¼0.79, P¼0.00056, see table 1).
Further evidence that the nucleotide variants detected in
the 10 LCLs with coverage in the B95-8 deletion are real
comes from their transition to transversion ratios (Ti/Tv), see
table 1. The Ti/Tv ratio for variants in the 61 LCLs infected
solely with the B95-8 strain is quite low (~1), indicating that
these variants are mostly sequencing errors. In the 10 individ-
uals with evidence of natural coinfection, the Ti/Tv ratio is
around 1.8 (1.77), closer to the ratio of 2, which is expected
in nature. For NA19114, NA19315, and NA19384 individuals,
with the highest proportion of endogenous EBV, the Ti/Tv
ratio in their 1,099 variants is even higher (1.86). Finally, we
observed that not a single variant is shared between the two
groups of LCLs: the 61 LCLs infected only with B95-8 and the
10 LCLs coinfected with endogenous EBV. The number of
variants called and the Ti/Tv ratios for each subset of individ-
uals can be found in supplementary table S1.2,
Supplementary Material online. In summary, all these obser-
vations, together with the practical absence of variability in the
B95-8 strain, indicate that rather than being mutations ac-
quired in vitro, the vast majority of the 1,535 variants are
due to the endogenous EBV virus which originally infected
the individuals sampled within the 1000 Genomes Project.
Therefore, with the exception of the RepeatMasked regions,
we can reconstruct the full EBV genome from these three
strains. Supplementary material S3, Supplementary Material
online, contains a detailed explanation about the effects of
applying different cut-offs on the accuracy of our variant call-
ing in our three LCLs.
Experimental Validation of the Presence of Natural
EBV Sequences
To prove experimentally the coexistence of different strains
in these LCLs and to validate the variants that we had
Table 1
Basic Statistics for the Ten Naturally Infected Individuals
IND Origin Mean EBV Mean Coverage
in Deletion
% of
Natural EBV
No. of
Variants
Mean Variants
AB (%)
Ts/Tv
NA20783 TSI 277.67 5.91 2.13 11 0.34 1.2
NA18507 YRI 115.22 3.08 2.67 27 0.06 1.455
NA20348 ASW 75.53 3.30 4.36 121 0.07 1.814
NA18923 YRI 68.24 3.18 4.66 77 0.07 2.208
NA20524 TSI 119.84 6.21 5.18 170 0.06 1.698
NA19114 YRI 246.15 38.38 15.59 445 0.17 1.967
NA19474 LWK 56.91 13.67 24.03 602 0.20 1.894
NA19315 LWK 62.84 18.04 28.70 628 0.25 1.881
NA19380 LWK 38.44 16.39 42.65 556 0.35 1.78
NA19384 LWK 36.16 29.56 81.75 576 0.70 1.73
NOTE.—Shadowed rows indicated individuals with a higher endogenous EBV proportion. AB, Allele balance; TSI, Toscani in Italia; ASW,
Americans of African ancestry in SW USA; YRI, Yoruba in Ibadan, Nigeria; LWK, Luhya in Webuye, Kenya.
FIG. 2.—Scatter plot where each dot indicates the number of variants
called in each LCL. Light blue dots represent LCLs with strong evidence of
the presence of natural EBV strains (from ten different individuals). The size
of the dot indicates the mean allele balance found in each LCL. Five LCLs
clearly show a large amount of genetic variation, as they harbor the great-
est proportion of natural EBV.
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determined, the DNA of the three LCLs for which we had
performed high-quality variant calling was obtained from
the Coriell Institute. Primers were designed to PCR amplify
fragments of the EBNA-2, LF2, and BBLF4 genes, spanning
regions containing called variants. By cloning and sequencing
we obtained and analyzed sequences from these individuals
(supplementary fig. S4.1, Supplementary Material online).
All the sequences we predict for the natural strain in these
individuals are always found and, thus, they are confirmed.
Moreover, all of the variants that we had previously identified
FIG. 3.—Genome Browser snapshot of the reads from the three individuals from which we obtained high-quality EBV genomes aligned against EBV type
1 (top panel) and type 2 (bottom panel) reference genome. The snapshot shows the EBNA-3region, which was used to discriminate EBV type 1 from type 2.
Large regions with no coverage are observed in the type 2 mappings, demonstrating that all three cell lines are infected only by type 1 EBV strains.
EBV Natural Strains from 1000G Project Individuals GBE
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in silico for NA19315, NA19384, and NA19114 were present
and, crucially, we did not find any new unpredicted variants at
a level of confidence that would allow for their calling, which
vouches for the completeness of our in silico analysis.
Additionally, the transforming strain sequence was detected
in fragments of the EBNA-2 and BBLF4 genes from all individ-
uals, and it was invariably identical to the B95-8 reference
sequence. As expected, LF2, a gene located in the B95-8
deletion, only presented natural sequences in all three LCLs.
These results confirm both the presence of natural viruses and
the high accuracy of our variant calling for individuals
NA19315, NA19114, and NA19834.
Classification of All the Available EBV Strains According
to Geography
We started by classifying the three genomes we had obtained
according to current criteria. To do so, we used a common
method of distinguishing EBV types that is based on the fact
that nucleotide differences in the EBNA-2 and EBNA-3 genes
are much higher between than within types, with large re-
gions being exclusive of one or other EBV type. Mapping EBV
reads from the diagnostic region EBNA-3A-3B-3C of the three
called individuals against the EBV type 2 reference genome
(fig. 3) shows no uniquely mapping reads in the large regions
exclusive of the EBV type 2 version of EBNA-3 genes, indicat-
ing that all natural EBV genomes present in these individuals
are type 1. Many substrains of EBV type 1 have been defined
by polymorphisms at genes such as EBNA-1, EBNA-2, LMP-1,
LMP-2a, or BZLF1. From such studies, some particular substi-
tutions are found predominantly in different regions of the
world. All the polymorphism from the three strains reported
here are consistent with the known African origin of the
donor individuals. (For a detailed analysis of polymorphisms
in these four genes, see supplementary material S5,
Supplementary Material online.)
To take advantage from full-genome information in
classifying EBV genomes, we performed a PCA including the
reference sequence plus all fully sequenced EBV strains that
are available in literature and presented low counts of ambig-
uous nucleotides (Lin et al. 2013): AKATA, GD1, MUTU, and
AG876 (fig. 4 and supplementary table S1.1, Supplementary
Material online). The first PC explains around 37% of variance
(P¼ 0.004) and separates type 1 from type 2 strains. The
second component explains around 27% of the variance
(P¼ 0.014) and separates Asian strains from African and ref-
erence strains.
Phylogenetic Relationships between EBV Strains
Constructing a phylogenetic tree with the eight high-quality
EBV sequences (three from the present study and five previ-
ously available best-quality sequences from diseased individ-
uals) confirms and expands the PCA results presented earlier.
It is immediately obvious from figure 5a that the AG876
branch is longer than any other, indicating greater divergence,
that NA19315 shares a common ancestor with MUTU, and
that all African plus B95-8/Raji strains are clearly separated
from the two Asian strains (AKATA and GD1). We repeated
the phylogenetic tree using only the 12 kb in the B95-8 dele-
tion (fig. 5b). Asian strains still appear separated from the rest,
NA19315 and MUTU remain in the same clade, but the
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FIG. 4.—PCA using all the SNVs in eight complete EBV strains. PC1 discriminates between type-1 and type-2 strains, while PC2 separates African from
Asian strains. A PC3 (marginally significant) does not place strains across a clear geographical axis, as NA18384 and MUTU have Kenyan origin. NA19384,
NA19315, and NA19114 in green; MUTU in red, GD1 and AKATA in gray; type 2 EBV in blue; and type 1 reference genome in black.
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classification of NA19384, NA19114, AG876, and Raji frag-
ment is unclear, probably due to lack of statistical power.
However, NA19114 and the Raji fragment still group to-
gether. It is noteworthy that the AG876 branch is now
much shorter and becomes integrated with most African
strains.
Finally, we reconstructed the tree excluding latency genes,
where most of intertypic variation is found (Dolan et al. 2006),
and observed (fig. 5c) that the AG876 branch is again shorter
and all African strains are clearly separated from Asians.
However, the tree from figure 5b shows that NA19384,
from Kenya, shares a most recent common ancestor with
Asian strains. These findings constitute clear proof that differ-
ent genomic regions present different genealogies. The most
likely cause is, of course, intertypic and intratypic recombina-
tion events.
Recombination between EBV Genomes
To try reconstructing the recombinational history of all the
available EBV genome sequences, we studied levels of identity
(a)
(b) (c)
FIG. 5.—Phylogenetic tree representing genetic distance between our three EBV strains and published sequences. Numbers in internal branches indicate
the consistency of the branch out of 1,000 bootstraps. Color gradient represents bootstrap support. Trees are rooted using the midpoint. (a) Phylogenetic
relationships using the whole EBV genome. (b) Using only the B95-8-specific deletion, which in the reference EBV genome corresponds to a Raji EBV strain
fragment from Nigeria. (c) Excluding latency genes, which contain most intertypic EBV variation.
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amongst sequences. We used Recco (Maydt and Lengauer
2006) to infer putative recombination breakpoints considering
each of our three genomes (one at a time) as the recombinant
product of the five good quality strains published so far. Then,
we determined “haplotype” blocks as pieces of sequence be-
tween any two breakpoints identified in any EBV genome.
Finally, we calculated an identity distance matrix for each
one of these blocks. Figure 6a and b shows that the EBV
genomes from NA19114 and NA19384 share haplotype
blocks mainly with B95-8/Raji and MUTU strains, with fewer
blocks closer to the Asian strains (GD1 and AKATA); while
NA19315 shows almost 100% block identity with MUTU
(fig. 6c). The same analysis performed on AG876 indicates
that its EBNA-2 and EBNA-3 blocks are divided among all
other genomes and show very low sequence identity
(supplementary fig. S6.1f, Supplementary Material online).
The rest of the EBV type-2 genome is divided in haplotype
blocks distributed evenly among the Asian and B95-8/Raji
strains. The genome of the B95-8/Raji strain appears as a com-
posite of MUTU and AG876 haplotypes plus a few AKATA
and GD1 blocks (supplementary fig. S6.1a, Supplementary
Material online). AKATA and GD1 strains can be reciprocally
explained (supplementary fig. S6.1d and e, Supplementary
Material online).
The Genomic Distribution of EBV Nucleotide Variants
As usual, different classes of genes present varying levels of
genetic diversity. We calculated Watterson’s estimate of y, the
parameter of neutral molecular evolution (Watterson 1975)
(a)
(b)
(c)
B95-8/Raji
AKATA
GD1
MUTU
AG876
NA19114
B95-8/Raji
AKATA
GD1
MUTU
AG876
NA19315
Block distance:  <5% <10% <15% >20%
B95-8/Raji
AKATA
GD1
MUTU
AG876
NA19384
FIG. 6.—Recco analysis on the three African EBV strains. We consider one sequence at a time to be the recombinant product of the rest of sequences.
Gray regions are masked due to repeats. The scale color is proportional to genetic distance based on identity, red indicates short distance, and yellow
indicates large distance. The first row is the one considered the recombinant product in all panels.
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using SNVs called in all coding regions and separately for
latency and lytic genes, as well as for UTRs and introns
(supplementary table S1.3, Supplementary Material online,
and fig. 7). Latency genes harbor more diversity than any
other element in the genome and they double the amount
of diversity found in the rest of coding elements. This trend
may be indicative of very different evolutionary pressures in
the two classes of genes.
As for genomic elements, they also present different levels
of variation (supplementary tables S1.3 and S1.4,
Supplementary Material online, and a more detailed descrip-
tion in supplementary material S5, Supplementary Material
FIG. 7.—Circos plot showing genome-wide single-nucleotide variant diversity in the three LCLs with the highest natural EBV load. Each green circle
corresponds to one individual. Red dots indicate variable positions. Blue dots indicate variants present in all three EBV sequences. The innermost circle shows
diversity on 500-bp windows considering all variants together. In the outer circle, latency genes (red) and lytic genes (blue) are represented. Light gray
shadows indicate repetitive regions, and dark gray sector indicates the location of the B95-8-specific deletion.
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online). Focusing on gene-disrupting mutations, we found a
mutation introducing a premature stop codon in the RPMS1
gene of the NA19315 sequence (nucleotide C160T, residue
Q54X). Although the RPSM1 ORF can be translated in vitro,
the RPMS1 protein has never been detected in natural infec-
tions (Al-Mozaini et al. 2009). Finally, two different frameshift
deletions were found in the LF3 coding region for NA19315
and NA19384. Both mutations create a new frame that pro-
duces a slightly longer version of LF3 version (supplementary
material S5, Supplementary Material online). It has been
shown that the LF3 coding frame is not conserved in
AKATA, and many start and stop codons in the 50 of the
gene in both AKATA and MUTU suggest a primary noncoding
function for LF3 (Lin et al. 2013).
Rates of Protein Evolution
Given that different genes present different diversity levels, it
makes sense to evaluate whether they are evolving at different
rates. The most widely used method to study rates of protein
evolution is to estimate the ratio between dN, the rate of
nonsynonymous substitutions along a branch of the phyloge-
netic tree, and the corresponding dS, the rate of synonymous
substitutions. Using the multiple sequence alignments of our
three EBV sequences coming from healthy individuals plus
the five known high-quality EBV strains, we calculated o
(the dN/dS ratio), for all coding regions by means of PAML’s
codeml (Yang 2007) and using the global tree. Supplementary
table S1.4, Supplementary Material online, shows the average
o value for all genes and for two different groups of genes:
those expressed during the lytic phase and those expressed
during latency. The average o value for lytic genes (0.22) in-
dicates that most EBV genes are under similar constraints than
average human genes (~0.25) (Kosiol et al. 2008). In contrast,
o is significantly increased in latency genes, with an average of
0.84 (Wilcoxon test P value 0.000015) (supplementary table
S1.4, Supplementary Material online).
We also studied dN/dS at the individual gene level in order
to identify particular genes under strong purifying or positive
selection. In general terms, genes that are very conserved at
the protein sequence level tend to be considered under strong
purifying selection, while, in contrast, genes with relatively
larger rates of nonsynonymous than synonymous changes
may have achieved that through the effect of adaptive evolu-
tion). We had estimated o values for each gene and obtained
likelihoods for every o value under the M0 model, considering
one o ratio for the whole tree. We then fixed o at 0.22 (the
average o value in lytic genes) obtaining a second likelihood
value, always under Model 0. Finally, we performed likelihood
ratio tests (LRTs) to determine what were the genes whose o
values were significantly different from 0.22. We performed
multiple test correction with a FDR q-value cut-off of 5%
(supplementary material S7, Supplementary Material online).
A total of 11 genes are under strong purifying selection, as
indicated by their significantly lowero values. Five of them are
related to DNA replication and nucleotide metabolism, includ-
ing BALF5 (the catalytic subunit of the viral DNA pol), BALF2
(part of the replication fork machinery), BBLF4 (helicase),
BGLF4 (kinase involved in many functions required for efficient
lytic DNA replication), and BORF2 (a ribonucleosidereductase).
One of the most conserved genes, BcLF1, encodes the major
capsid protein (MCP), which self-assembles in pentamers and
hexamers to form the virus capsid. Three other very
constrained genes are BALF3, BGRF1, and BBRF1, which are
involved in DNA packaging inside the capsid during the lytic
phase. Interestingly, the other two genes are related to
tegument and cell attachment (BSRF1) and/or interaction
with host proteins (LF2, which interacts with IRF7).
We then repeated the codeml Model 0 analysis fixing o to
1 (the expected value of o under neutrality) and compared
with the same model with free o. Only EBNA-1, which
encodes for essential proteins for the establishment and main-
tenance of EBV latency, presented a o value significantly
greater than one (o¼ 1.78). This constitutes evidence that
the EBNA-1 gene has been under positive selection.
We found six nonlatency genes to be accelerated relative to
average o values found in lytic genes. BRRF2 and BFRF2
encode for two viral tegument proteins with unknown func-
tions. BRRF2 is known to be expressed and translated because
peptides BRRF2 were abundantly detected in LCLs (Johannsen
et al. 2004). BFRF2 has only clear evidence at transcript level
(Concha et al. 2012). BARF0 has evidence at transcript level
but may not be translated in vivo. Finally and more interest-
ingly, we found BKRF2, BLLF1, and BLLF2 to be accelerated.
BKRF2 encodes for the envelope glycoprotein L required for
the fusion of viral and plasma membranes for a virus to be able
to enter into the host cell and interact with the host’s integrins
(Connolly et al. 2011). BLLF2 ORF comprised BLLF1 coding
region. BLLF1 encodes for gp350, which initiates the virus
attachment to the host’s cells via interaction with B cells
CR2 (Young et al. 2008).
One potential problem can arise from forcing a single tree
topology produced by whole-genome alignment to genes
that have different genealogies, as we did in the calculations
above, because assuming the wrong tree may lead to mises-
timation ofo. To control for that source of error, we estimated
o under all possible tree topologies produced by eight
sequences (supplementary material S8, Supplementary
Material online). In general, o estimates for latency genes
are robust to different tree topologies. In particular, o is
significantly higher than 1 (P< 0.05) in 88.3% of the possible
tree topologies of EBNA-1. Similarly robust o values are
observed also in lytic genes BLLF1 and BRRF2. However, o
estimates for BLLF2, BFRF2, and BKRF2 seem to be more
affected by tree topology, making these measures less reliable
(supplementary material S8, Supplementary Material online).
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It is possible that, even if a gene as a whole is under strong
purifying selection, some of its codons or groups of codons
have been the targets of positive selection. In order to test
specifically for this hypothesis while controlling for contribu-
tion of a relaxation of selective constraints, we performed
another codeml analysis that compares two different models
that allow variation of o values between codons. The first
model (M8) allows a subset of codons to have o greater
than one. That model is usually tested against a null model
that does not permit any codons to have o greater than 1
(M7). Even when using a 5% q-value cut-off, the LTRs showed
that M8 explained our data better than M7 in eight of the
latency genes: EBNA-1, -3A, -3B, -3C, -LP, LMP-1, and
LMP-2A, which seem to have undergone accelerated evolu-
tion under the influence of positive selection. BLLF1, BLLF2,
BARF0, BFRF2, and BRRF2 but not BKRF2 also show this sig-
nature at codon level. In addition, 20 other genes whose o
values are not particularly high and, thus, did not show up in
the previous analyses also bear the signature of adaptive evo-
lution (supplementary material S7, Supplementary Material
online). Two examples are BNRF1, which encodes the major
tegument protein (MTP) involved in virus entry, attachment,
and membrane fusion, and BVRF2, encoding one capsid
protein and BFRF1A and BFLF1, which are involved in packag-
ing; the later being also responsible for placing capsids in the
nuclear replication compartments. Finally, we detected
signatures of positive selection at some codons in genes
whose complete sequence appears particularly constrained
such as BALF2 and BALF3, indicating putative functional sites.
Discussion
We have carried out the most complete comparative geno-
mics study of EBV so far. To do so, we combined published
EBV genomes from diseased donors with our own survey of
sequence data from the 1kG Project, which provided EBV
genomes from healthy individuals. In total, we deeply ana-
lyzed eight EBV genome sequences.
One major obstacle that we had to overcome to carry out
our study was the presence of the B95-8 transforming strain
in most of the 1kG Project LCLs (~92%). However, we could
obtain clear evidence of co-occurring natural EBV strains in 10
out of 946 individuals. Given the high prevalence of EBV in-
fection, the number of individuals in which we observe co-
occurrence of natural EBV may seem surprisingly low. To
understand that apparent paradox, we need to consider that
in healthy individuals (such as those from the 1kG Project), EBV
persists in peripheral blood B cells at a frequency of about 1–50
infected cells per million B cells (Babcock et al. 1998). Given
that around 2 million B cells are contained in 1 ml of blood, we
would expect to find low counts of infected lymphocytes per
blood extraction. Moreover, only ~3% of the peripheral leu-
kocytes of adult donors become immortalized by EBV (Sugden
and Mark 1977). This clearly reduces the chances of a B95-8
transformation of an already naturally infected B cell. In addi-
tion, although initially EBV-immortalized B-cell lines are poly-
clonal, after prolonged culture in vitro, cell lines become
oligoclonal or monoclonal (Ryan et al. 2006). Except for a
small subset of immune-compromised individuals, most EBV-
associated tumors and LCLs contain monoclonal EBV (Gulley
et al. 1994). This monoclonality may be indicative either of
genetic drift or of natural selection among cell clones. At any
rate, the most common scenario is that a few clones quickly
become dominant (Ryan et al. 2006), reducing the probability
of finding clones infected with the natural EBV relative to
clones infected only with the B95-8 strain.
Nevertheless, it is likely that by increasing sequencing cov-
erage in 1kG Project samples, it would be possible to detect
more LCLs with some wild-type EBV. Actually, a recent study
provides analyses of publicly available RNA-seq data from 319
LCLs derived from 143 individuals (Arvey et al. 2012), some of
them overlapping our set of samples. By looking at their pub-
lished RPKM values (Reads per Kilo Base per Million) of the LF3
gene, which is located in the deletion of the B95-8 transform-
ing strain, we can deduce that at least 76 LCLs (~50%) con-
tain some load of natural EBV strains.
Infections by multiple EBV strains are most commonly ob-
served in immunocompromised individuals (Tierney et al.
2006), but also happen in healthy individuals (Lung et al.
1988; Walling et al. 2003). Regarding only the two major
EBV types, rates of coinfection of EBV type 1 and type 2
range from 0% to 53% (Kunimoto et al. 1992; Srivastava
et al. 2000; Walling et al. 2003). High frequency of coinfection
with both type 1 and type 2 EBV has been reported in MS
patients (Santo´n et al. 2011). Given that we do not find evi-
dence of coinfection by different natural EBV types, it is worth
noting that we might have underestimated intraindividual EBV
diversity if our variants came only from a dominant isolate or
the LCLs that were sequenced within the 1kG Project were the
result of a selection bias toward transformation-competent
EBV isolates (Tierney et al. 2006). By amplifying and cloning
fragments of EBV of our three LCLs with strong evidence of
natural coinfection, we have been able to prove the existence
and accuracy of our predicted natural strains, as well as the
existence of major dominant isolates of natural EBV coexisting
in these studied LCLs.
Are the Variants Determined Really Natural?
Several facts support that the variants we have studied were
wild-type variants present in the B cells of 1kG Project individ-
uals before the establishment of LCLs. The strongest piece of
evidence is that LCLs with no sign of coinfection by natural
EBV contain very low levels of polymorphism, which given
their low Ti/Tv ratio and extreme values of allele balance are
likely to be sequencing errors. In this subset of 61 LCLs, we
observed an average of only five low-quality variants per LCL,
so it is unlikely that B95-8 variants are biasing our results. In
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fact, the opposite is more likely: we cannot rule out that traces
of natural EBV could account for some of the variants that we
attribute to B95-8. Cloning and Sanger sequencing of frag-
ments of EBV provide conclusive evidence that the B98-5 ver-
sion of these fragments is identical to the published reference
sequence. In short, we have determined that the B95-8 strain
possesses a very stable genome that does not present any
relevant contribution to the pool of variants that we deter-
mined in our three natural strains. The same experiment also
validated the confidence of our variant calling in the evaluated
EBV fragments. However, an inherent limitation in our data
remains. Given the contribution of reads of both natural and
transforming strain, however the small the later may be, it is
not possible to guarantee the total absence of false-negative
variant calls. As explained in supplementary material S3,
Supplementary Material online, this is particularly true for
NA19315, but we estimate that even in the worst case sce-
nario in which all very low frequency variants were true pos-
itives, in NA19315 we would still have a ~94% of sensitivity.
Phylogeny and Recombination
Phylogeny is not always consistent in different regions of the
EBV genome, allowing the inference of recombination events,
as previously reported by McGeoch and Gatherer (2007). By
studying genomic blocks delimited by predicted recombina-
tion breakpoints, we observed that current haplotypes are
mixed inter- and intratypically. EBV type2 (AG876) is in fact
a composite of high-identity blocks already present in all
known type 1 strains. It has been proposed that the EBV
type 2 strains come from a type 1 prototype strain that incor-
porated EBNA-2 and EBNA-3 blocks from a closely related
lymphocryptovirus (McGeoch 2001). Given the crucial role
of these genes in latency establishment, it has been hypothe-
sized that such acquisitions increased the virus’ fitness as
EBNA-2 and EBNA-3 blocks from type 1 and type 2 were
maintained in the present combinations relative to a possible
recombinant version between type 1 and type 2 (McGeoch
2001). Another possibility would be that intensive substitution
processes in those genes were driven by positive selection
(McGeoch 2001). Having said that, inter-typic recombinants
showing recombination breakpoints in the EBNA-3 gene block
have been reported in healthy and immunecompromised in-
dividuals from different geographical regions (Midgley et al.
2000, 2003; Go¨rzer et al. 2006). During productive EBV rep-
lication, intrastrain homologous and nonhomologous recom-
bination events can occur and have been observed in
repetitive regions of the genome (Walling et al. 1992;
Walling and Raab-Traub 1994; Walling et al. 1999). Thus,
our results warrant caution in classifying EBV strains: recom-
bination events may confound relatively simple classifications
based on single-gene polymorphisms such as those found in
the EBNA-1 gene.
Rates of Protein Evolution in EBV Genes
We analyzed SNV and INDEL polymorphism in our three
strains in relation to the B95-8/Raji reference genome and
observed that diversity found in latency related genes is the
highest compared with any other genomic element. EBV
genome comparison between simian homologs of EBV had
revealed that some latency genes diverged faster (Wang et al.
2001). Confirming and expanding these results, we found
that diversity in latency genes doubles the level of nucleotide
variation found in lytic genes and is even higher than diversity
found in introns. We calculated o values, studied the signa-
tures of selection for all coding regions in EBV, and compared
different selection models using a LRT. We acknowledge the
well-known fact that accuracy and power of the LRT for
detecting selection on genes depend on the number of
sequences, with power being 100% at ~15 sequences
(Anisimova et al. 2001). By adding our three new sequences
to five already reported EBV genomes, we increase the power
to detect positive selection acting on genes; however, we still
might be underpowered for some low-divergence genes. In
particular, the limitations of site-prediction methods are
greater when assessing protein evolution rates at the codon
level (Nozawa et al. 2009) and thus it is clear that experimental
validation of putatively selected residues would be needed.
Our analysis provides evidence for the action of both puri-
fying and positive selection. The average o value of lytic genes
resembles the average of ~0.25 found in primates (Kosiol
et al. 2008), indicating similar evolutionary constraints in
viral and host genes. We reported evidence for strong purify-
ing selection acting upon 11 EBV genes. These include genes
encoding proteins that work in crucial enzymatic activities
such as the viral DNA polymerase (BALF5) or the helicase func-
tion (BBLF4). One host-interacting element has also been the
target of purifying selection: LF2. LF2 binds the central inhib-
itory association domain of IRF7, inhibiting the interferon-me-
diated immunity, which is the major defense raised by the host
against viral infections (Wu et al. 2009).
Latency genes, in contrast, present higher o values, indicat-
ing that positive selection may be the cause of their high di-
versity levels. Using various models we observed that EBNA-1,
-3A, -3B, -3C, -LP, LMP-1, and LMP-2A contain a subset of
codons, which have experienced positive selection. The action
of positive selection inferred from an increased proportion of
nonsynonymous variation has already been described in LMP-1
and EBNA-1 (McGeoch and Davison 1999; Walling et al.
1999). In addition to these genes, other coding regions related
to virus attachment and entry in host cells (BLLF1 and BKRF2)
show signatures of accelerated protein evolution rates. BRRF2
and BFRF2 present a higher o value and, together with BNRF1
and three other capsid and packaging-related genes, also
show evidence of positive selection at codon level. BNRF1 en-
codes for the MTP. The BRRF2 protein has been abundantly
detected in LCLs by means of mass spectrometry (Johannsen
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et al. 2004), and it is likely that both constitute viral tegument
proteins. As these kinds of proteins can regulate viral attach-
ment and immune evasion of viruses, evidence of selection in
BLLF1, BKRF2, MTP, BRRF2, and BFRF2 suggests that knowl-
edge may be gained from a detailed analysis of genetic varia-
tion in these genes in different populations and pathology
groups and from the study of functional implications of
these variants in the biology and pathogenesis of EBV.
Supplementary Material
Supplementary materials S1–S9 are available at Genome
Biology and Evolution online (http://www.gbe.oxfordjour-
nals.org/).
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